Supplementary Table 1. Characteristics of the included patients

|  |  |  |
| --- | --- | --- |
|  | Global Population (N = 188) | Included Patient (N = 134) |
| Continuous covariates | Value [min-max] | |
| Age (years) | 64 [31-79] | 63 [31-78] |
| Height (cm) | 161 [148-180] | 162 [148-180] |
| Weight (kg) | 64 [40-103] | 63.50 [42-103] |
| Categorical covariates | n (%) | |
| FIGO stage at randomization |  |  |
| Stage IIIc | 140 (74) | 103 (77) |
| Stage IV | 45 (24) | 31 (23) |
| Missing data | 3 (2) | 0 (0) |
| FIGO stage at diagnosis |  |  |
| Stage IIIc | 144 (77) | 105 (78) |
| Stage IV | 41 (22) | 29 (22) |
| Missing data | 3 (2) | 0 (0) |
| Histology |  |  |
| Others | 23 (12) | 14 (10) |
| Serous/papillary | 162 (86) | 120 (90) |
| Missing data | 3 (2) | 0 (0) |
| Histological grade |  |  |
| Grade 1 | 5 (3) | 4 (3) |
| Grade 2 | 13 (7) | 9 (7) |
| Grade 3 | 133 (71) | 99 (74) |
| Missing data | 37 (20) | 22 (16) |
| Treatment Arm |  |  |
| Placebo | 61 (32) | 47 (35) |
| Nintedanib | 124 (66) | 87 (65) |
| Missing data | 3 (2) | 0 (0) |
| GCIG CA-125 Response |  |  |
| Unfavorable | 41 (22) | 41 (31) |
| Favorable | 93 (49) | 93 (69) |
| Missing data | 54 (29) | 0 (0) |
| Completeness of the interval debulking surgery |  |  |
| Incomplete | 93 (49) | 67 (50) |
| Complete | 92 (49) | 64 (48) |
| Missing data | 3 (2) | 3 (2) |
| Disease risk-group\* |  |  |
| Low-risk group | 72 (38) | 51 (38) |
| High-risk group | 110 (59) | 80 (60) |
| Missing data | 6 (3) | 3 (2) |
| BRCA 1 or 2 mutation |  |  |
| Yes | 10 (5) | 8 (6) |
| No | 17 (9) | 13 (10) |
| Missing data | 161 (86) | 113 (84) |
| Radiological response at end of neo-adjuvant therapy |  |  |
| Complete | 5 (4) | 4 (3) |
| Partial | 67 (36) | 52 (40) |
| Stable | 91 (48) | 70 (52) |
| Progression | 3 (2) | 2 (1) |
| Missing data | 22 (10) | 6 (4) |

\*High-risk group: Stage IV and incompletely resected stage III disease